Overview

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
Phase:
Phase 2
Details
Lead Sponsor:
ARCA Biopharma, Inc.